Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer حسب Kaizhao Hu (15670612)

"…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …"

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer حسب Kaizhao Hu (15670612)

"…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …"

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer حسب Kaizhao Hu (15670612)

"…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …"

Variation law of AE <i>b</i>-value of sandstone under different freeze-thaw cycles at a loading rate of 0.20mm/min. حسب Wenyu Lv (20139458)

الموضوعات:

Variation law of AE <i>b</i>-value of sandstone under different freeze-thaw cycles at a loading rate of 0.05 mm/min. حسب Wenyu Lv (20139458)

الموضوعات:

RBM-26 binds to the <i>mals-1</i> mRNA and negatively regulates its expression. حسب Tamjid A. Chowdhury (14149846)

RTA408 significantly reduces RGCs loss in glaucoma. حسب Hongmei Qian (538647)

Age-standardized prevalence rates of gynecological diseases across 21 GBD regions, by SDI, from 1990 to 2021. حسب Xiaofeng He (2618752)

الموضوعات:

Additional questions on vaccination. حسب Sara Saleh (6733619)

الموضوعات:

The raw data file. حسب Sara Saleh (6733619)

الموضوعات:

Implementation framework. حسب Amos Asiedu (4996946)

"…HMIS data showed statistically significant improvement in data completeness (from 62 to 87% (p < 0.001)) and decreased error rate (from 37 to 18% (p < 0.001)) after completion of the coaching visit series. …"

Age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. حسب Xiaofeng He (2618752)

الموضوعات:

Estimated annual percentage change in age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. حسب Xiaofeng He (2618752)

الموضوعات:

Estimated annual percentage changes in the prevalence rate of specific gynecological diseases from 1990 to 2021, categorized by age group and SDI. حسب Xiaofeng He (2618752)

الموضوعات:

Prevalence and trends of gynecological diseases (GDs) among women of childbearing age, by age group and SDI. حسب Xiaofeng He (2618752)

الموضوعات:

Prevalence of gynecological diseases (GDs) among women of childbearing age in 2021, along with their changes from 1990 to 2021, and the contribution of each GD to the overall preva... حسب Xiaofeng He (2618752)

الموضوعات:

DHIMS2 data quality over time. حسب Amos Asiedu (4996946)

"…HMIS data showed statistically significant improvement in data completeness (from 62 to 87% (p < 0.001)) and decreased error rate (from 37 to 18% (p < 0.001)) after completion of the coaching visit series. …"

Fig 1 - حسب Sara Hintze (3216885)

الموضوعات:

Test apparatus. حسب Sara Hintze (3216885)

الموضوعات:

The raw data used in this study. حسب Yu Fu (16582)

الموضوعات: